Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Door Opens For Barr To Acquire Pliva As Actavis Bows Out Of Bidding War

This article was originally published in The Pink Sheet Daily

Executive Summary

Hurdles for completing the acquisition still exist for Barr, which must acquire majority of Pliva shares.

You may also be interested in...



Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit

Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.

Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit

Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.

Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA's Generics Unit

Ranbaxy and Actavis are two potential bidders vying for Merck KGaA's generics drug unit, an acquisition that would solidify either company as the third largest generics drug maker in the world

Related Content

Topics

UsernamePublicRestriction

Register

PS064871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel